Tong Liumei, Xu Huiliang
Department of Medical Oncology, Shaoxing Second Hospital, Shaoxing 312000, P.R.China.
J BUON. 2019 Nov-Dec;24(6):2294-2302.
This study aimed to detect the levels of cytokeratin 7 (CK7) and thyroid transcription factor -1(TTF-1) in serum of patients with non-small cell lung cancer (NSCLC) complicated with superior vena cava syndrome (SVCS), and to explore their prognosis and relationship and correlation with pathological characteristics.
68 patients with non-small cell lung cancer (NSCLC) complicated with SVCS treated in Shaoxing Second Hospital from July 2014 to May 2018 were selected as the experimental group, 60 normal healthy persons as the control group, and 60 patients with lung cancer as the lung cancer group. The levels of CK7 and TTF-1 in the three groups were determined by enzyme-linked immunosorbent assay (ELISA), and the differences were compared. The relationship between the expression levels of CK7 and TTF-1 and clinicopathological characteristics of patients, the correlation between CK7 and TTF-1 in lung cancer patients complicated with SVCS, and their 3-year survival rate were analyzed.
CK7 and TTF-1 levels in experimental group were significantly higher than those in control group (P<0.05). The levels in lung cancer group were significantly higher than those in control group (P<0.05). In experimental group, the expression of CK7 and TTF-1 was not related to gender, age, weight, histological classification and tumor size (P>0.05)). CK7 expression was positively correlated with TTF-1 expression in lung cancer patients (P<0.001). The 3-year survival rate in CK7 and TTF-1 high expression group was significantly lower than that in low expression group (P<0.05).
The expressions of CK7 and TTF-1 are increased in patients with lung cancer complicated with SVCS, and are related to TNM stage, lymph node metastasis and differentiation degree. The high expressions of CK7 and TTF-1 in serum of patients are expected to be potential prognostic indicators for lung cancer complicated with SVCS.
本研究旨在检测非小细胞肺癌（NSCLC）合并上腔静脉综合征（SVCS）患者血清中细胞角蛋白7（CK7）和甲状腺转录因子-1（TTF-1）水平，探讨其与预后的关系以及与病理特征的相关性。
选取2014年7月至2018年5月在绍兴第二医院治疗的68例非小细胞肺癌合并SVCS患者作为实验组，60例正常健康人作为对照组，60例肺癌患者作为肺癌组。采用酶联免疫吸附测定（ELISA）法测定三组患者CK7和TTF-1水平，并比较差异。分析CK7和TTF-1表达水平与患者临床病理特征的关系、肺癌合并SVCS患者中CK7与TTF-1的相关性及其3年生存率。
实验组CK7和TTF-1水平显著高于对照组（P<0.05）。肺癌组水平显著高于对照组（P<0.05）。在实验组中，CK7和TTF-1的表达与性别、年龄、体重、组织学分类和肿瘤大小无关（P>0.05）。肺癌患者中CK7表达与TTF-1表达呈正相关（P<0.001）。CK7和TTF-1高表达组的3年生存率显著低于低表达组（P<0.05）。
肺癌合并SVCS患者CK7和TTF-1表达升高，且与TNM分期、淋巴结转移及分化程度有关。患者血清中CK7和TTF-1高表达有望成为肺癌合并SVCS的潜在预后指标。
